Search results
Results from the WOW.Com Content Network
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
On Sept. 25, BioAge's stock proceeded with its IPO, which raised gross proceeds of $238.3 million. Before the IPO, it had raised $321 million via several rounds of funding with private investors ...
This year has seen more than its share of successful IPOs – and some giant flops. The extremes should have been expected, in a year with a record number of new public offerings. The second ...
A Rivian R1S All-Electric SUV is displayed at the 2019 New York International Auto Show in New York City, U.S, April 17, 2019. REUTERS/Brendan McDermid (Brendan McDermid / reuters)
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
Pharmacia spins off its Monsanto subsidiary into a new company, [1] the "new Monsanto" - which then raises $700 million in a new IPO. [32] The "new Monsanto" is legally distinct from the old pre-2000 Monsanto. 2000: Competition: Syngenta is formed in 2000 by the merger of Novartis Agribusiness and Zeneca Agrochemicals. [33] [34] By 2009, it ...
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies.
For the year: the company was at the bottom of the Annual Top 25 Biotech Companies for the year as judged by staff of Genetic Engineering & Biotechnology News. [67] 28 March: the company announces it will develop 12 more drugs, employing another 100 staff. [66]